R&D Projects

ZITOMAB

Second-generation antitumor immunotherapies: antibodies and toxin-conjugated nanobodies using Inteins-ZIP

The aim of the project is the development of a specific antibody conjugation platform through the application of ZIP-Inteins® technology, which is based on the use of inteins as a conjugation tool.

4

organisations participate in the project

detailGrey

The project’s innovative strategy will allow access to previously inaccessible areas inside solid tumours.

In order to successfully achieve the project’s aims, a consortium has been formed led by Zera Intein Protein Solutions S.L., in collaboration with Acondicionamiento Tarrasense – LEITAT, and Fundació Institut de Recerca biomédica (Barcelona).

To achieve the objectives

RTC-2015-4336-1 2015-2018

The project has been financed by the Ministry of Science, Innovation and Universities within the RETOS-COLABORACIÓN Subprogram, 2015 Call. Co-financed by the European Union with the aim of promoting technological development, innovation and quality research.

Financial backers

Related projects

ADELIS

ADELIS

Pharmacogenomic evaluation for the treatment of breast cancer with aromatase inhibitors

Read more
BLI-O

BLI-O

Development of molecular markers to identify long survivors with immunotherapy

Read more
METABREAST

METABREAST

Determination of metabolomic profiles in the early diagnosis of breast cancer.

Read more
APTALUNG

APTALUNG

Lung cancer diagnostics based on aptamer technology

Read more